DeepMed Research

CHIESI FARMACEUTICI S.P.A.

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1935-01-01

Employees: -

Market Cap: -

Website: http://www.chiesigroup.com

Clinical Trials

Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

Not yet recruiting

Conditions: Fabry Disease
Pregnancy
Pregnancy Complications

First Posted Date: 2025-04-23

Last Posted Date: 2025-04-23

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 10

Registration Number: NCT06941025

Locations: 🇬🇧
No physical study sites - Decentralized, web-based registry, London, United Kingdom

A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa

Phase 3

Not yet recruiting

Conditions: Epidermolysis Bullosa
Junctional Epidermolysis Bullosa
Epidermolysis Bullosa, Dystrophic
Epidermolysis Bullosa, Junctional
Skin Abnormalities
Congenital Abnormalities
Connective Tissue Disease
Collagen Diseases
Skin Diseases
Genetic Diseases, Inborn

Interventions: Drug: Oleogel-S10

First Posted Date: 2025-04-08

Last Posted Date: 2025-04-08

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 6

Registration Number: NCT06917690

Locations: 🇯🇵
Kurume University Hospital, Fukuoka, Japan
🇯🇵
Niigata University Medical and Dental Hospital, Niigata, Japan
🇯🇵
Hokkaido University Hospital, Sapporo-shi, Japan

A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001

Phase 2

Recruiting

Conditions: Asthma

Interventions: Drug: CHF 6001

First Posted Date: 2025-03-28

Last Posted Date: 2025-04-27

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 50

Registration Number: NCT06900816

Locations: 🇧🇬
Medical Centre Comac Medical Ltd., Sofia, Krasno Selo District, Bulgaria

Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) Study

Phase 1

Recruiting

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: CHF6001 dry powder inhaler (DPI)
Drug: Cyclosporine
Drug: CHF6001 DPI

First Posted Date: 2025-03-25

Last Posted Date: 2025-04-02

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 24

Registration Number: NCT06892756

Locations: 🇧🇬
Medical Centre Comac Medical Ltd, Sofia, Bulgaria

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF10073 After Single and Multiple Doses in Healthy Volunteers

Phase 1

Recruiting

Conditions: Pulmonary Fibrosis

Interventions: Drug: CHF10073 (Part 1 - SAD)
Drug: Placebo (Part 1 - SAD)
Drug: CHF10073 (Part 2 - MAD)
Drug: Placebo (Part 2 - MAD)
Drug: CHF10073 (Part 3)

First Posted Date: 2024-12-24

Last Posted Date: 2025-01-24

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 132

Registration Number: NCT06746064

Locations: 🇧🇪
SGS Belgium NV Clinical Pharmacology Unit, Edegem, Belgium

A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients

Recruiting

Conditions: Fabry Disease

Interventions: Drug: Pegunigalsidase-alfa

First Posted Date: 2024-10-29

Last Posted Date: 2024-11-18

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 100

Registration Number: NCT06663358

Locations: 🇺🇸
Infusion Associates, Grand Rapids, Michigan, United States

Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients (TRIPHY)

Recruiting

Conditions: Chronic Obstructive Pulmonary Disease

First Posted Date: 2024-06-28

Last Posted Date: 2025-04-24

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 359

Registration Number: NCT06480890

Locations: 🇨🇳
Site 156125 - Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
🇨🇳
Site 156122 - Deyang People's Hospital, Deyang, Sichuan, China
🇨🇳
Site 156124 - Lishui People's Hospital, Lishui, Zhejiang, China

and more 19 locations

Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: CHF6001 DPI
Drug: Erythromycin

First Posted Date: 2024-05-02

Last Posted Date: 2024-07-03

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 24

Registration Number: NCT06395610

Locations: 🇧🇬
MC Comac Medical Ltd., Sofia, Bulgaria

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

Phase 2

Recruiting

Conditions: Fabry Disease

Interventions: Drug: PRX-102 1 mg/kg every two weeks

First Posted Date: 2024-03-25

Last Posted Date: 2024-12-20

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 22

Registration Number: NCT06328608

Locations: 🇺🇸
Phoenix Children's, Phoenix, Arizona, United States
🇺🇸
Emory Genetics Clinical Trials Center, Atlanta, Georgia, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States

and more 9 locations

Comparison Between CHF5993 pMDI 200/6/12,5mg HFA-152a VS CHF5993 pMDI 200/6/12,5mg HFA-134a in Subjects With Asthma (Trecos)

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: CHF5993 200/6/12.5 μg pMDI HFA-152a
Drug: Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a

First Posted Date: 2024-02-20

Last Posted Date: 2025-04-04

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 836

Registration Number: NCT06264674

Locations: 🇦🇲
Yerevan State Medical University, Heratsi N 1 University Hospital Complex, Yerevan, Armenia
🇦🇲
CITO Medical Center, Yerevan, Armenia
🇦🇲
Armenia Republican Medical Center, Yerevan, Armenia

and more 139 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy